First patient dosed in Phase Ib Pompe disease trial
The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.
Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe ...
Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...
The Lancet19 天
Evidence for a reduction in number of cycles of immune checkpoint inhibitors
A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...
Pharmaceutical Technology22 天
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Elraglusib is aimed at treating pancreatic ductal adenocarcinoma. Credit: Jo Panuwat D/Shutterstock. Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European ...
Yahoo Finance23 天
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for ...
07, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of ...
C&EN23 天
Bisubstrate Analog Inhibitors of DXP Synthase Show Species Specificity
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States Chemistry-Biology Interface Graduate Training Program, Johns ...